X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pyrimidinones - pharmacology (2154) 2154
science & technology (1992) 1992
humans (1970) 1970
life sciences & biomedicine (1893) 1893
animals (1482) 1482
male (965) 965
pharmacology & pharmacy (942) 942
female (688) 688
pyrimidinones - chemistry (681) 681
pyrimidinones - chemical synthesis (594) 594
mice (581) 581
pyrimidinones - therapeutic use (524) 524
rats (511) 511
structure-activity relationship (479) 479
lopinavir (468) 468
adult (394) 394
pyrimidinones - administration & dosage (373) 373
biochemistry & molecular biology (354) 354
cell line, tumor (352) 352
chemistry (340) 340
pyrimidinones - pharmacokinetics (333) 333
dose-response relationship, drug (328) 328
hiv infections - drug therapy (298) 298
middle aged (287) 287
molecular structure (284) 284
physical sciences (282) 282
chemistry, medicinal (275) 275
oncology (255) 255
antineoplastic agents - pharmacology (238) 238
cell line (218) 218
mutation (203) 203
infectious diseases (202) 202
enzyme inhibitors - pharmacology (201) 201
pyridones - pharmacology (190) 190
pyrimidinones - metabolism (188) 188
analysis (187) 187
protein kinase inhibitors - pharmacology (184) 184
in vitro techniques (183) 183
cell biology (180) 180
hiv-1 - drug effects (180) 180
pyrimidinones - adverse effects (177) 177
models, molecular (174) 174
thiazoles - pharmacology (172) 172
cell proliferation - drug effects (163) 163
hiv (160) 160
ritonavir - therapeutic use (159) 159
kinetics (157) 157
microbiology (155) 155
cells, cultured (153) 153
treatment outcome (150) 150
aged (149) 149
drug therapy, combination (149) 149
pyrimidinones (147) 147
rats, sprague-dawley (144) 144
chemistry, organic (143) 143
pyridines - pharmacology (143) 143
cancer (141) 141
antiviral agents (140) 140
research (139) 139
time factors (137) 137
drug design (135) 135
hiv protease inhibitors - pharmacology (135) 135
ritonavir - administration & dosage (135) 135
drug therapy (131) 131
disease models, animal (129) 129
virology (129) 129
pyrimidinones - blood (127) 127
administration, oral (123) 123
apoptosis (121) 121
immunology (119) 119
drug interactions (118) 118
hiv protease inhibitors - therapeutic use (118) 118
dogs (117) 117
hiv infections - virology (117) 117
pharmacology (117) 117
apoptosis - drug effects (115) 115
microbial sensitivity tests (115) 115
cell survival - drug effects (112) 112
protease inhibitors (111) 111
pharmacokinetics (109) 109
proteins (109) 109
protein binding (104) 104
signal transduction (104) 104
pyrimidines - pharmacology (103) 103
ritonavir - pharmacokinetics (103) 103
ritonavir - pharmacology (101) 101
xenograft model antitumor assays (100) 100
sulfonamides - pharmacology (99) 99
drug synergism (97) 97
signal transduction - drug effects (96) 96
abridged index medicus (95) 95
binding sites (95) 95
biophysics (95) 95
anti-hiv agents - pharmacology (93) 93
hiv protease inhibitors - administration & dosage (93) 93
anti-hiv agents - therapeutic use (92) 92
hiv protease inhibitors - pharmacokinetics (91) 91
ritonavir (91) 91
antiviral agents - pharmacology (90) 90
calcium - metabolism (89) 89
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3111) 3111
Japanese (78) 78
German (30) 30
Chinese (12) 12
Russian (10) 10
Spanish (10) 10
French (7) 7
Italian (3) 3
Polish (3) 3
Portuguese (3) 3
Ukrainian (3) 3
Hungarian (2) 2
Croatian (1) 1
Czech (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature communications, ISSN 2041-1723, 10/2017, Volume 8, Issue 1, pp. 1090 - 19
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 02/2015, Volume 125, Issue 3, pp. 1269 - 1285
Journal Article
Nature communications, ISSN 2041-1723, 12/2014, Volume 5, Issue 1, pp. 5712 - 5712
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Prognosis | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - metabolism | Signal Transduction | Proto-Oncogene Proteins - genetics | Imidazoles - pharmacology | Melanoma - pathology | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aminopyridines - pharmacology | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Oximes - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Microphthalmia-Associated Transcription Factor - genetics | Pyridones - pharmacology | Index Medicus
Journal Article
Cancer discovery, ISSN 2159-8290, 06/2012, Volume 2, Issue 6, pp. 524 - 539
Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies.... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Protein Kinases - metabolism | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Apoptosis - drug effects | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Quinolines - pharmacology | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | DNA-Binding Proteins - metabolism | Deoxycytidine - therapeutic use | Cyclins - metabolism | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pyrazoles - pharmacology | Cell Line | Pyrimidinones | Thiophenes - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Breast Neoplasms - drug therapy | Enhancer of Zeste Homolog 2 Protein | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Polycomb Repressive Complex 2 | Urea - therapeutic use | Animals | Mitosis - drug effects | Tumor Burden - drug effects | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | S Phase - drug effects | Thiazoles - pharmacology | Deoxycytidine - analogs & derivatives | Urea - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Current topics in medicinal chemistry, ISSN 1568-0266, 2004, Volume 4, Issue 10, pp. 1079 - 1095
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in... 
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Anti-HIV Agents - pharmacology | Pyridines - chemistry | Humans | Saquinavir - therapeutic use | Urethane - chemistry | Pyrimidinones - chemistry | Oligopeptides - therapeutic use | HIV Protease Inhibitors - pharmacology | Saquinavir - pharmacology | Urethane - therapeutic use | Atazanavir Sulfate | Phenylbutyrates - pharmacology | Ritonavir - therapeutic use | Oligopeptides - chemistry | Saquinavir - chemistry | Lopinavir | Pyrimidinones - therapeutic use | Models, Molecular | Sulfonamides - pharmacology | HIV Protease Inhibitors - therapeutic use | Nelfinavir - pharmacology | Anti-HIV Agents - chemistry | Carbamates | Urethane - pharmacology | Oligopeptides - pharmacology | Organophosphates - therapeutic use | Indinavir - pharmacology | Urethane - analogs & derivatives | HIV - drug effects | Molecular Mimicry | Phenylbutyrates - chemistry | Anti-HIV Agents - therapeutic use | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Molecular Structure | Pyridines - therapeutic use | Nelfinavir - therapeutic use | Peptides - chemistry | Sulfonamides - chemistry | Dipeptides - pharmacology | HIV Protease Inhibitors - chemistry | Clinical Trials as Topic | Dipeptides - chemistry | Ritonavir - chemistry | Peptides - pharmacology | Organophosphates - pharmacology | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Organophosphates - chemistry | Pyridines - pharmacology | Peptides - therapeutic use | Indinavir - therapeutic use | Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
Abstract Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Index Medicus | Abridged Index Medicus | Symposium on Antimicrobial Therapy
Journal Article